Commentary: Iloprost for cholesterol emboli syndrome

BMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7337.609 (Published 09 March 2002) Cite this as: BMJ 2002;324:609
  1. Charles D Pusey, professor of renal medicine
  1. Faculty of Medicine, Imperial College, Hammersmith Hospital, London W12 0NN

    The following letter was commissioned by the BMJ as a commentary to accompany the research pointer published on 2 February. Owing to a failure of our processes we did not publish the commentary alongside the article. We are therefore publishing it now with apologies to Professor Pusey and our readers.

    In a recent research pointer Elinav et al describe four cases of cholesterol emboli syndrome treated with iloprost.1 Their main observations were improvement in distal extremity ischaemia in all cases and improvement in renal function in the one patient with acute renal impairment.

    Cholesterol emboli syndrome …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription